Dementia Partnerships
Technology appraisal TA217 Alzheimer's disease – donepezil, galantamine, rivastigmine and memantine
This guidance replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009). Read more »
Archives
Psychotropic medicine management for people in care homes with dementia
This guidance aims to support the safe management of psychotropic medicines in Norfolk care homes particularly when given to residents to assist in managing their psychological agitation. Read more »
Audit of antipsychotic therapy in dementia patients in Hampshire
This audit of antipsychotic therapy in patients with dementia was undertaken by NHS Hampshire to ensure it is safe and complies with local guidance. Read more »
Prescribing review: Acetyl Cholinesterase inhibitors
This audit was undertaken by North Staffordshire Combined Healthcare NHS Trust to establish compliance with NICE Technology Appraisal Guidance 111 on the use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately severe Alzheimer’s disease. Read more »
Prescribing guidelines: Acetyl Cholinesterase inhibitors
These prescribing guidelines developed by Berkshire Healthcare NHS Foundation Trust support GPs on the use of Acetyl Cholinesterase inhibitors (ChEIs) for the treatment of Alzheimer’s dementia in accordance with NICE guidance. Read more »
The use of antipsychotic medication for people with dementia: Time for action
The report explores the current evidence base, the law, and practice relating to prescription of antipsychotic medication for people with dementia. Read more »